Contact:
4008465777
-
About Us
News & Events
-
05-08
Tonghua Dongbao Introduces GLP-1 Semaglutide Injection
Recently, Tonghua Dongbao Pharmaceutical Co., Ltd. (hereinafter referred to as "Tonghua Dongbao" or "the Company") signed the Commercialization Licensing and Marketing Authorization Holder (MAH) Agree...
-
05-07
Tonghua Dongbao: First Patient Dosed in Phase IIa Clinical Trial of Dual Inhibitor for Gout (THDBH151 Tablets)
Recently, Dongbao Zixing (Hangzhou) Biopharmaceutical Co., Ltd., a wholly owned subsidiary of Tonghua Dongbao Pharmaceutical Co., Ltd. (hereafter referred to as "Tonghua Dongbao" or "the Company") suc...
-
04-27
Tonghua Dongbao Releases 2024 Q1 Report
On April 26, Tonghua Dongbao Pharmaceutical Co., Ltd. (stock code: 600867, hereinafter referred to as "Tonghua Dongbao" or “the Company") released its 2024 Q1 report. During the reporting period, the...
-
04-25
Tonghua Dongbao announces NMPA approval of clinical trial application for dual GLP-1/GIP receptor agonist (THDBH120 injection) intended for weight loss indications
Recently, Dongbao Zixing (Hangzhou) Biopharmaceutical Co., Ltd. ("Dongbao Zixing"), a wholly owned subsidiary of Tonghua Dongbao Pharmaceutical Co., Ltd. (the "Company" or "Tonghua Dongbao") received ...
-
04-24
Tonghua Dongbao's Entire Insulin Lineup Secures Category A in the VBP Program, With Two Types Categorized as A1
On April 23, 2024, China's Joint Procurement Office (JPO) announced the preliminarily selected bids from a continued round of the national volume-based procurement (VBP) program for insulin. This ...
-
03-29
Tonghua Dongbao releases 2023 sustainability report
On March 28, Tonghua Dongbao Pharmaceutical Co., Ltd. (stock code: 600867, hereinafter referred to as "Tonghua Dongbao" or the "Company") released its 2023 sustainability report. The report disclosed ...